ReviewFrontiers in immunology2019
Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors.
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed.
- Efficient multiplex non-viral engineering and expansion of polyclonal γδ CAR-T cells for immunotherapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- LRRC15-CAR T Cells for the Treatment of Osteosarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Harnessing Vδ1Frontiers in immunology · 2026Review
- Cas9-induced targeted integration of large DNA payloads in primary human T cells via homology-mediated end-joining DNA repair.Nature biomedical engineering · 2024Article
- A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.Journal of experimental & clinical cancer research : CR · 2024Article
- DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.Cell reports. Medicine · 2024Article
- PD-1 defines a distinct, functional, tissue-adapted state in Vδ1Nature cancer · 2024Article
- A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Review
- Computational Methods in Immunology and Vaccinology: Design and Development of Antibodies and Immunogens.Journal of chemical theory and computation · 2023Review
- Local γδ T cells: translating promise to practice in cancer immunotherapy.British journal of cancer · 2023Review
- Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer.Cancer immunology, immunotherapy : CII · 2023Article
- ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype.Frontiers in oncology · 2023Article
- Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy.Cancer gene therapy · 2022Review
- Article
- Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction.Cancer cell international · 2022Review
- Minimally Invasive Preclinical Monitoring of the Peritoneal Cavity Tumor Microenvironment.Cancers · 2022Article
- Treatments on the Horizon: Breast Cancer Patients with Central Nervous System Metastases.Current oncology reports · 2022Review
- Optimized two-step electroporation process to achieve efficient nonviral-mediated gene insertion into primary T cells.FEBS open bio · 2022Article
- Impact of Manufacturing Procedures on CAR T Cell Functionality.Frontiers in immunology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Immunotherapy with chimeric antigen receptor (CAR) T cells offers a promising method to improve cure rates and decrease morbidities for patients with cancer. In this regard, CD19-specific CAR T cell therapies have achieved dramatic objective responses for a high percent of patients with CD19-positive leukemia or lymphoma. Most patients with solid tumors however, have experienced transient or no benefit from CAR T cell therapies. Novel strategies are therefore needed to improve CAR T cell function for patients with solid tumors. One obstacle for the field is limited CAR T cell persistence after infusion into patients. In this review we highlight genetic engineering strategies to improve CAR T cell persistence for enhancing antitumor activity for patients with solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.